Marksans Pharma Limited has announced that its wholly owned subsidiary in the United Kingdom, Relonchem Limited, has obtained Marketing Authorization from the UK Medicines and Healthcare products Regulatory Agency (MHRA) for its product Exemestane 2
The latest portable ultrasound device, Sonosite MT, by FUJIFILM Sonosite, is the addition to the point-of-care product range, PX, LX, and the ST. The stand provides clinicians with flexibility as the clamshell-like MT can be utilized with or...
In a moment that transcended medical victory, Ujwala Chavan, a 37-year-old from Mumbai, recently sat down to a simple, solid meal; an act most take for granted, but one she had been waiting 14 years to experience...
For the first time, Sun Pharmaceutical has seen its U.S. sales of innovative medicines overtake generics in the second quarter of FY26, marking a major shift for India’s largest drug maker. The surge came on the back of strong sales of Ilumya...
.png "Lupin's Pithampur Unit-3 Secures US FDA EIR Approval")
Lupin Limited, a global pharmaceutical company, has received the Establishment Inspection Report (EIR) of the Lupin Pithampur Unit-3 plant in Madhya Pradesh. This report is a follow-up to a successful inspection conducted between July 7 and...
Venus Remedies, one of the world’s top 10 manufacturers of fixed-dosage injectable drugs, has received new marketing authorizations in Vietnam for three key products methotrexate, cefuroxime, and irinotecan. These latest approvals strengthen the
Medicity, one of India’s premier super-speciality hospitals and Best Private Hospital in India, and it has unveiled its Advanced Surgical Heart Failure Clinic a state-of-the-art centre focused on the diagnosis, surgical treatment
Morgan Stanley PE-backed Omega Hospitals, based in Hyderabad, has successfully acquired Cytecare Hospitals, a prominent cancer care facility located in Bengaluru. This strategic acquisition signifies Omega's entry into a rapidly expanding
Cupid Ltd., a health and wellness products leading manufacturer, revealed that it foresees producing annual revenue of Rs 115 crore from the South African market, after its achievement of securing the largest allocation
Sun Pharmaceutical Industries Ltd has in Q2 of 2026 financial year, to a large extent, sold innovative medicines in the US market than generics. The achievement was a result of a robust market demand for Ilumya
, CDSCO.jpg "Fostering a Quality Culture in the Pharmaceutical Industry")